Blood cell count is not a significant predictor of survival in bladder cancer after radical cystectomy

Main Article Content

Andy Andy
Fauriski Febrian Prapiska
Ginanda Putra Siregar
Syah Mirsya Warli
Bungaran Sihombing


Radical cystectomy (RC) is the gold standard treatment for muscle-invasive bladder carcinoma. A predictive factor is needed for the aggressive approach as it could lead to overtreatment. Elevated blood cell count (BCC) markers are reported to have a significant association with poor outcomes in several types of malignancy. Neutrophil-to-lymphocyte-ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are well-known inexpensive and effective representative markers of inflammatory conditions. This study aimed to determine the BCC as a predictive factor of overall survival (OS) in patients with bladder carcinoma (BC) after RC.

A retrospective cohort study was conducted involving 26 patients who had undergone RC. The demographic characteristics and BCC markers such as hemoglobin (Hb). NLR, PLR and lymphocyte/monocyte ratio (LMR) were collected. The patients were categorized based on the BCC marker value (³ median and < median). Kaplan–Meier survival analysis was done to determine overall survival (OS) on BCC markers. The association between patient demographics and one-year survival was also determined using Mantel-Cox (Log-rank) method.

Among the 26 patients, the mean age was 55.6 ± 12.9 years. On univariate analysis, none of the demographic characteristics was found to be a significant predictor of one-year and overall survival (p>0.05). Hemoglobin, NLR, PLR and LMR were not significant predictors of one-year survival and OS (p>0.05).

The BCC was not a significant predictive factor of survival in patients with bladder cancer after radical cystectomy.

Article Details

How to Cite
Andy, A., Prapiska, F. F., Siregar, G. P., Warli, S. M., & Sihombing, B. . (2021). Blood cell count is not a significant predictor of survival in bladder cancer after radical cystectomy . Universa Medicina, 40(2), 148–156.
Original Articles


Kaseb H, Aeddula NR. Bladder cancer. Treasure Island (FL): StatPearls Publishing; 2020.

Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol 2019;38:1895-904. doi: 10.1007/s00345-019-02984-4.

Wahafu W, Liu S, Xu W, et al. The long-term efficacy of one-shot neoadjuvant intra-arterial chemotherapy combined with radical cystectomy versus radical cystectomy alone for bladder cancer: a propensity-score matching study. BMC Urol 2019;19:117.

Çelen S, Kaygýsýz O, Vuruþkan H, Yavaþcaoðlu Ý. Laparoscopic versus open radical cystectomy in the treatment of locally advanced T3 and T4 bladder cancer: Perioperative and mid-term oncological outcomes. Turk J Urol 2020;46:123-8. doi: 10.5152/tud.2020.19077.

Pane K, Mirabelli P, Coppola L, Illiano E, Salvatore M, Franzese M. New roadmaps for non-muscle-invasive bladder cancer with unfavorable prognosis. Front Chem 2020;8:600. doi: 10.3389/fchem.2020.00600.

McAlpine K, Fergusson DA, Breau RH, et al. Radiotherapy with radical cystectomy for bladder cancer: a systematic review and meta-analysis. Can Urol Assoc J 2018;12:351-60. doi: 10.5489/cuaj.5244.

Bhindi B, Hermanns T, Wei Y, et al. Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. Br J Cancer 2016; 114:207-12. doi: 10.1038/bjc.2015.432.

Rajwa P, ¯yczkowski M, Paradysz A, Bujak K, Bryniarski P. Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy. Eur Rev Med Pharmacol Sci 2018;22:3027-37. doi: 10.26355/eurrev_201805_15060.

Kumar R, Geuna E, Michalarea V, et al. The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials. Br J Cancer 2015;112:1157–65.

Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012;107:695-9. doi: 10.1038/bjc.2012.292.

Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 2018;32:1267-84. doi: 10.1101/gad.314617.118..

Zhou X, Du Y, Huang Z, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One 2014;9:e101119. doi: 10.1371/journal.pone. 0101119.

Luo Y, Shi X, Li W, et al. Evaluation of the clinical value of hematological parameters in patients with urothelial carcinoma of the bladder. Medicine (Baltimore) 2018;97:e0351. doi: 10.1097/MD. 0000000000010351.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;4;144:646-74. doi: 10.1016/j.cell.2011.02.013.

Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 2015;125:3347-55. doi: 10.1172/JCI80007.

Lee SM, Russell A, Hellawell G. Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma. Korean J Urol 2015;56:749-55. doi: 10.4111/kju.2015.56.11.749.

Thanan R, Oikawa S, Yongvanit P et al. Inflammation-induced protein carbonylation contributes to poor prognosis for cholangiocarcinoma. Free Radic Biol Med 2012; 52:1465-72. doi: 10.1016/j.freeradbiomed.2012. 01.018.

Thanan R, Pairojkul C, Pinlaor S, et al. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. Free Radic Biol Med 2013;65:1464-72. doi: 10.1016/j. freeradbiomed.2013.07.034.

Mossel DM, Moganti K, Riabov V, et al. Epigenetic regulation of S100A9 and S100A12 expression in monocyte-macrophage system in hyperglycemic conditions. Front Immunol 2020;11:1071. doi: 10.3389/fimmu.2020.01071.

Kuderer NM, Poniewierski MS, Culakova E, et al. Predictors of venous thromboembolism and early mortality in lung cancer: results from a global prospective study (CANTARISK). Oncologist 2018;23:247-55. doi: 10.1634/theoncologist.2017-0205.

Lee BM, Chung SY, Chang JS, Lee KJ, Seon J. The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are prognostic factors in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Gut Liver 2018; 12:342-52.

Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 2014;134:2403-13. doi: 10.1002/ijc.28536.